On December 11, 2025, Mr. Matthew Fosbery, Deputy Commercial Consul of Australia in Chengdu and Trade & Investment Commissioner of Austrade, and Ms. Wang Ming, Commercial Officer of Austrade, visited Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) for inspection and exchanges, and had in-depth discussions on international cooperation in the vaccine field. Mr. Fan Shaowen, Chairman of Olymvax, Mr. Wu Wei, Board Secretary, and Mr. Meng Jun, Business Development Director, warmly received and accompanied the inspection.
At the symposium, Chairman Fan Shaowen introduced the Company’s internationalization strategy layout in detail, focusing on a series of measures such as business development in Australia and technical cooperation with local scientific research institutions. As a biopharmaceutical enterprise deeply engaged in innovative vaccines, Olymvax has continuously promoted the “Going Global” strategy in recent years. In 2025, it further deepened cooperation with Griffith University of Australia and successfully signed a GAS vaccine entrusted production agreement, demonstrating internationally recognized vaccine production strength. Consul Matthew Fosbery spoke highly of Olymvax’s achievements in Australian business development and technological innovation capabilities, believing that its measures have set a model for practical cooperation in the medical and health field between China and Australia, and looked forward to further promoting bilateral resource sharing and policy connectivity in the future. The two sides also exchanged views on vaccine R&D, integration of government and enterprises, facilitation and other topics.
After the meeting, accompanied by the Company’s management, Consul Matthew Fosbery and his entourage visited the influenza vaccine production workshop of Olymvax. The workshop adopts the domestically leading MDCK cell suspension culture technology, eliminating the need for chicken embryo culture. It has advantages such as high yield, small batch-to-batch variation and short production cycle, and can realize large-scale bioreactor production. The relevant quadrivalent influenza vaccine has entered the Phase III clinical trial stage. The advanced production equipment, strict quality control system and cutting-edge technical route left a deep impression on the inspection group. Consul Matthew Fosbery praised the Company’s investment in vaccine process upgrading and innovative R&D.
This visit injected new impetus into Olymvax to deepen the Australian market layout and expand China-Australia vaccine cooperation. In the future, Olymvax will continue to aim for “Internationally Renowned, Domestically Leading”, rely on innovative pipelines and technical advantages, promote more high-quality vaccine products to the world, and contribute Chinese wisdom and strength to safeguarding global public health security.
